Psychedelic Therapy Training for Psychotherapists in Canada (2026 Guide)

Canadian Registered Psychotherapists (CRPO Ontario), permit-holding psychothérapeutes (OPQ Quebec), and Master's-level psychotherapists in other provinces are well-positioned to deliver the psychotherapy components of psychedelic-assisted therapy. This guide covers CRPO and OPQ scope, the legal landscape for the three substances (ketamine off-label, psilocybin SAP, MDMA SAP), continuing-education recognition, training programs in Canada, and how psychotherapists integrate into multidisciplinary PAT teams.

Key takeaways

• Registered Psychotherapists (RPs) hold the controlled act of psychotherapy in Ontario; OPQ permit-holders hold the equivalent restricted scope in Quebec. Both groups can legally deliver the psychotherapy components of PAT — preparation, in-session support, and integration — within authorized clinical-trial or SAP-approved programs [CRPO; OPQ Regulation C-26 r.222.1].
• RPs and psychothérapeutes cannot prescribe, administer, or possess any controlled substance, and cannot apply through Health Canada's Special Access Program; SAP authority rests with physicians and nurse practitioners [CRPO; BCACC 2024].
• Ketamine-assisted therapy is the most accessible PAT context for psychotherapists today because ketamine is an approved medicine and SAP is not required; psilocybin and MDMA require physician-led SAP applications.
• Health Canada's December 2022 risk-management notice explicitly requires "a minimum of two therapists present" during dosing, with at least one "licensed to provide psychotherapy by a regulatory body." RPs in Ontario and OPQ-permit psychothérapeutes in Quebec satisfy this requirement directly [Health Canada 2022].
• CRPO's Continuing Competency Program requires 40 hours of professional development per 2-year cycle (20 hours/year minimum) plus 750 currency hours per rolling 3-year period. OPQ permit-holders must complete 90 hours of CE in psychotherapy per 5-year period [CRPO; OPQ].

Why Registered Psychotherapists are well-positioned for psychedelic work

Atomic answer: Psychotherapists already hold the core competencies that PAT outcomes depend on: therapeutic alliance, trauma-informed framework, integration of altered or non-ordinary emotional states, and clinical attunement to set and setting. A meta-analysis of 295 studies (over 30,000 patients) confirms therapeutic alliance as a robust predictor of psychotherapy outcomes (r=0.278) [Flückiger et al. 2018]. In psilocybin trials specifically, stronger pre-session alliance predicted greater emotional breakthrough and lower depression scores at 4 weeks, 6 months, and 12 months post-treatment [Murphy et al. 2022; Levin et al. 2024]. Phelps's foundational competency framework names empathetic abiding presence, trust enhancement, and self-awareness among the six core PAT competencies [Phelps 2017] — competencies psychotherapists develop throughout their training.

Specialized PAT training adds three layers on top of existing psychotherapy competence: substance-specific pharmacology and physiology, supervised dosing-day skills, and the regulatory literacy to operate within Canadian frameworks (Health Canada SAP, provincial physician colleges, CRPO/OPQ scope rules). The Cavarra et al. (2022) systematic review of psychotherapy components across 26 PAT trials found that preparation, in-session support, and integration are universal structural features [Cavarra et al. 2022]; psychotherapists are the natural delivery profession for these components.

The legal landscape for psychotherapists in 2026

PAT in Canada operates under two distinct legal tracks for psychotherapists:

Ketamine-assisted therapy: ketamine is a Health Canada-approved anaesthetic prescribed off-label for psychiatric indications. Psychotherapists deliver the psychotherapy components within a multidisciplinary team led by a prescribing physician or nurse practitioner. No SAP is required; provincial physician colleges (CPSA Alberta, CPSM Manitoba, CPSBC BC, CPSO Ontario) set the operational rules [CPSA 2026; CPSM 2026; CPSBC 2025].

Psilocybin and MDMA: both remain restricted drugs accessible only through Health Canada's Special Access Program. Psilocybin SAP is primarily granted for treatment-resistant major depressive disorder and end-of-life distress; MDMA SAP is primarily granted for PTSD [Health Canada 2022]. Psychotherapists cannot apply through SAP — the application must come from a prescribing physician or nurse practitioner. PsyCan documented an approximately 50 percent decline in SAP approvals through 2025, making this the more constrained pathway [PsyCan 2025].

CRPO neither endorses nor prohibits PAT for Ontario RPs but is currently in the process of developing PAP-specific guidance [CRPO]. Until that guidance is published, RPs operate under existing standards: the controlled act of psychotherapy applies (Standard 1.4), prescribing is outside scope, and competency expansion requires consultation and supervision (Standard 2.1).

CRPO requirements and competency expansion

CRPO's Practice Standards (effective January 1, 2024) establish what RPs in Ontario can and cannot do in PAT contexts.

What RPs can do (per Standard 1.4.2): perform the controlled act of psychotherapy "provided they have the competence to do so in a safe and effective manner." Authorized modalities include cognitive-behavioural, experiential and humanistic, somatic, psychodynamic, and systemic therapies — all relevant to PAT delivery.

What RPs cannot do (per Standard 1.4.1 and CRPO PAP resource): "RPs are not authorized to prescribe medication, give advice about medication or communicate a diagnosis." RPs also cannot be in possession of illegal substances, cannot practise while impaired, must act within their area of competence, and must collaborate with care-team members.

Continuing Competency Program (Quality Assurance):

• 40 hours of professional development per 2-year cycle (minimum 20 hours per year)
• At least one didactic activity and at least one experiential activity per cycle
• 750 currency hours of psychotherapy-related activities on a rolling 3-year basis
• Self-assessment at least every two years
• Case-Based Assessment approximately every five years (30 situational judgment cases, 80% pass)

CRPO does not maintain a list of accredited CE providers. PAT training programs (TheraPsil, Numinus, ATMA CENA) count toward the 40-hour requirement at the registrant's judgment, provided the training is relevant to practice, credible, and documented.

CRPO's PAP Resource Article explicitly directs registrants expanding into PAT to review Standard 2.1: Seeking Consultation, Clinical Supervision, and Referral. The Standard states that "knowing when to seek clinical supervision or consultation, and when to refer a client to another professional is integral to a registrant's professional obligations." Documenting consultation, supervision, and competency development is the professional record RPs maintain when expanding into PAT [CRPO Resource Article].

CRPO Standard 6.2 (Advertising) prohibits client testimonials, superlatives, comparisons to others, and outcome promises. RPs cannot advertise PAT services without verifiable training. Advertising must be "truthful, accurate, factual, and verifiable."

The OPQ psychothérapeute pathway (Quebec)

In Quebec, both the title psychothérapeute and the act of psychotherapy are restricted under the Professional Code and the Regulation respecting the psychotherapist's permit (C-26 r.222.1). The permit is issued by Ordre des psychologues du Québec (OPQ) to members of six regulated orders (guidance counsellors, occupational therapists, nurses, psychoeducators, social workers, marriage and family therapists). Physicians and psychologists practise psychotherapy under their own frameworks without a separate permit.

Authorized theoretical models under the regulation: psychodynamic, cognitive-behavioural, systemic, and humanist. PAT-relevant approaches (somatic, internal-family-systems, mindfulness-based, integration models) generally fit within these frameworks.

OPQ continuing-education requirement: 90 hours of CE in psychotherapy per 5-year period. Non-compliance triggers practice restrictions or permit suspension. OPQ has formally approved CE credit for the leading PAT training programs:

• TheraPsil Fundamentals of Psilocybin-Assisted Psychotherapy: 30 OPQ hours
• Numinus Fundamentals of Psychedelic-Assisted Therapy: 63 OPQ hours

In a PAT context, Quebec psychothérapeutes can deliver preparation, in-session support, and integration psychotherapy as part of a physician-led team operating under SAP authorization or within an approved clinical trial. They cannot prescribe or administer.

Psychotherapist-specific training programs in Canada (2026)

Canadian psychotherapists evaluating PAT training have several options. Recognition by CRPO (for RPs) is via the registrant's QA program — CRPO does not accredit individual programs. OPQ recognition for psychothérapeutes is formal where listed.

The Vancouver Island University Graduate Certificate in Psychedelic-Assisted Therapy was discontinued in November 2025; clinicians who were exploring that academic pathway may consider ATMA CENA's Clinical Pathway or TheraPsil's Fundamentals as Canadian-context alternatives.

ATMA CENA's Supervised Learning Lab explicitly lists Registered Psychotherapists, Certified Canadian Counsellors, Clinical Social Workers, and nurses in psychotherapy roles in its eligible audience. The 4-session, 8-hour cohort format with maximum 8 participants is structured for the small-group practicum experience CRPO Standard 2.1 supports.

Ready to see the full Clinical Pathway? Review course details, cohort dates, pricing, and CE credits for Registered Psychotherapists and allied mental-health clinicians.

Ketamine-assisted therapy: the most accessible clinical pathway

Ketamine is a Health Canada-approved anaesthetic prescribed off-label for depression, anxiety, PTSD, and chronic pain. Unlike psilocybin and MDMA, ketamine does not require SAP authorization. For psychotherapists, this makes ketamine-assisted therapy (KAT) the most immediately accessible PAT context after training.

The peer-reviewed evidence supports the psychotherapist's distinct contribution. Drozdz et al. (2022) — a Canadian-led systematic narrative review of 17 KAP studies — found that "psychotherapy, provided before, during, and following ketamine sessions, can maximize and prolong benefits" across pain, anxiety, and depressive symptoms [Drozdz et al. 2022]. Wilkinson et al. (2017) demonstrated that 10 weeks of cognitive-behavioural therapy delivered after IV ketamine sustained antidepressant response in 75 percent of ketamine responders at 8 weeks — establishing psychotherapist-delivered integration as a relapse-prevention mechanism [Wilkinson et al. 2017]. The largest Canadian KAP effectiveness study (n=346 at 3 months, n=94 at 6 months) at Field Trip Health clinics in Toronto, Vancouver, and Fredericton documented sustained large effect sizes (Cohen's d 0.61–0.86) using a protocol that integrates motivational interviewing and trauma-informed integration techniques delivered by therapist team members [Yermus et al. 2024].

Provincial-college rules govern the team and facility configuration. In Alberta, KAT delivered as part of psychedelic-assisted psychotherapy must occur in a CPSA-accredited facility with psychiatrist or physician-in-consultation oversight [CPSA 2026]. In British Columbia, non-IV ketamine routes are governed by CPSBC's interim guidance v1.3 (August 2025) [CPSBC 2025]. In Manitoba, CPSM published current ketamine prescribing guidance in January 2026 [CPSM 2026]. In Ontario, CPSO has not issued a ketamine-specific policy.

Psilocybin and MDMA training: preparing for SAP-supported practice

For psilocybin and MDMA, psychotherapists train to operate within Health Canada's SAP framework as part of physician-led teams. The two-therapist model embedded in MAPS-protocol MDMA-assisted therapy uses a team where at least one clinician must be "licensed to provide psychotherapy by a regulatory body (if applicable in their jurisdiction)" — language that directly fits Ontario RPs and Quebec OPQ-permit psychothérapeutes [Health Canada 2022].

The Phase 3 MAPP1 trial of MDMA-assisted therapy used three preparation sessions (90 minutes each), three experimental sessions (8 hours each), and nine integration sessions per participant within the manualized two-therapist model. MAPP1 found 67 percent of MDMA-group participants no longer met DSM-5 PTSD criteria at the primary endpoint of 18 weeks compared to 32 percent in the placebo-with-therapy group, with an effect size of Cohen's d = 0.91 [Mitchell et al. 2021]. The MAPP2 confirmatory Phase 3 trial replicated the result (71.7% response rate vs 60% placebo, d = 0.7) [Mitchell et al. 2023]. Wang et al. (2021) demonstrated that therapist dyads — including master's-level practitioners — achieved 95 percent fidelity to the manualized protocol across multiple North American sites, including Canadian sites [Wang et al. 2021].

For psilocybin, two pivotal RCTs anchor the evidence base. Goodwin et al. (2022) in the New England Journal of Medicine found a single 25 mg dose produced a between-group MADRS difference of 6.6 points versus a 1 mg control at week 3 in 233 patients with treatment-resistant depression [Goodwin et al. 2022]. Raison et al. (2023) in JAMA found a 25 mg dose vs niacin placebo produced a 12.3-point MADRS difference at day 43 with sustained response in 42 percent of psilocybin patients vs 11 percent placebo [Raison et al. 2023]. Both trials used structured psychological support delivered by therapist dyads.

Psychotherapists trained in MDMA or psilocybin protocols can serve in the therapy team for SAP-authorized patients, in clinical trial sites, and increasingly in expanded-access programs as Canadian regulation evolves. PsyCan's September 2025 documentation of declining SAP approvals reinforces that the immediate clinical opportunity is in KAT; psilocybin and MDMA training prepares clinicians for sanctioned-program participation rather than free clinical practice [PsyCan 2025].

Building a psychedelic practice within your existing registration

Trained psychotherapists integrate into PAT practice through three structures: clinical-trial sites, SAP-authorized programs led by a prescribing physician, or structured clinic-network models that handle medical and regulatory infrastructure.

Documentation, informed consent for off-label use, supervision arrangements, and liability coverage that explicitly includes PAT are professional-practice prerequisites psychotherapists arrange before active practice. CRPO Standard 1.5.1 and OPQ permit-holder rules require informed-consent documentation; off-label and SAP-context informed consent has additional disclosure requirements per CMPA's March 2026 off-label drug guidance.

Training complete? Bring PAT into your existing practice. The coordinated care model lets Registered Psychotherapists treat their own clients inside ATMA CENA clinics — maintaining the therapeutic relationship while accessing full medical infrastructure. Learn how coordinated care works.

Province-by-province snapshot for psychotherapists

Title protection and regulatory framework vary materially across Canadian provinces.

For psychotherapists practising in jurisdictions without title protection, scope flows from the primary regulated profession. Health Canada's expectation that team therapists be "licensed to provide psychotherapy by a regulatory body (if applicable in their jurisdiction)" is satisfied by the practitioner's primary credential where psychotherapy is not separately regulated [Health Canada 2022].

Frequently asked questions

Can a CRPO Registered Psychotherapist deliver psychedelic-assisted therapy in Ontario?

Yes — within the controlled act of psychotherapy and the CRPO scope rules. RPs can deliver preparation, in-session support, and integration psychotherapy as part of a multidisciplinary team led by a prescribing physician. RPs cannot prescribe, administer, or possess any controlled substance. CRPO is currently developing PAP-specific guidance; until published, registrants apply existing standards, particularly Standards 1.4 (Controlled Acts) and 2.1 (Consultation, Supervision, Referral) [CRPO].

Does a CRPO RP need specific accreditation to practise PAT?

CRPO does not require specific PAT certification for Ontario RPs as of May 2026. Practice within scope, with documented competency development through the 40-hr/2-yr Continuing Competency Program and ongoing supervision per Standard 2.1, satisfies CRPO's professional-conduct requirements. Specialty PAT training programs (TheraPsil, Numinus, ATMA CENA) count toward the CCP at the registrant's judgment.

What's the difference between a Registered Psychotherapist and a psychothérapeute under OPQ?

In Ontario, "Registered Psychotherapist" (RP) is the protected title under CRPO. In Quebec, "psychothérapeute" is the protected title under OPQ; the OPQ issues the psychotherapist's permit to members of six regulated orders. Both are restricted titles in their respective provinces; Quebec additionally restricts the act of psychotherapy in a more granular way. The two regulatory frameworks differ but share similar scope outcomes: both groups can deliver psychotherapy within authorized PAT teams; neither can prescribe or administer.

Can a Quebec psychothérapeute count TheraPsil's psilocybin training toward the 90-hour CE requirement?

Yes — TheraPsil's Fundamentals of Psilocybin-Assisted Psychotherapy is OPQ-approved for 30 CE hours. Numinus's Fundamentals is OPQ-approved for 63 hours. The 90-hours/5-years requirement applies to permit-holders specifically; activities must be documented and retained.

What does the CRPO Continuing Competency Program require?

40 hours of professional development per 2-year cycle (minimum 20 hours per year), with at least one didactic and at least one experiential activity. RPs maintain 750 currency hours of psychotherapy-related activities on a rolling 3-year basis. Self-assessment occurs at least every two years; Case-Based Assessment occurs approximately every five years (30 situational-judgment cases, 80 percent pass). Annual attestation by March 31 [CRPO].

Can an RP advertise psychedelic-assisted therapy services?

CRPO Standard 6.2 requires advertising to be "truthful, accurate, factual, and verifiable" and prohibits client testimonials, superlatives, comparisons, and outcome promises. RPs may "advertise an area of practice only if they have verifiable training in that area of practice." Translation: an RP can describe PAT-relevant services after completing verifiable training, but cannot use client testimonials, cannot claim outcomes, and cannot use superlatives.

What happens after I complete training as a psychotherapist?

Trained psychotherapists join PAT delivery through clinical-trial sites, SAP-authorized programs led by a prescribing physician, or structured clinic-network models such as ATMA CENA's coordinated care. coordinated care requires completion of at least 50 hours of Clinical Pathway training and provides clinical protocols, operational systems, and access to the network of trained clinicians.

Which ATMA CENA pathway is right for psychotherapists?

The Clinical Pathway is the primary route for RPs and OPQ permit-holders who will deliver the therapeutic components of PAT including dosing-day support. The Integrative (Essentials) Pathway is appropriate for psychotherapists focused on integration-only practice without dosing-day involvement. The Prescriber Pathway is for physicians and nurse practitioners and not applicable to psychotherapists.

Is personal psychedelic experience required to train?

Health Canada SAP protocols do not mandate personal psychedelic experience as a training prerequisite. Some training programs offer or require experiential components (TheraPsil includes experiential as part of in-person delivery); others do not. The peer-reviewed argument for firsthand experience as a competency-relevant element [Dames et al. 2024] is one position in an active professional discussion rather than a settled clinical standard. Different programs make different choices on this question.

How does the two-therapist model work in MDMA-assisted therapy clinical trials?

MAPP1 and MAPP2 used a manualized protocol with co-therapist dyads where at least one therapist held a Master's degree or higher and at least one was licensed to provide psychotherapy under a regulatory body. Wang et al. (2021) demonstrated that master's-level practitioners (including counsellors and psychotherapists) achieved 95 percent fidelity to the manualized protocol across multiple North American trial sites including Canadian sites [Wang et al. 2021]. RPs and OPQ permit-holders are well-positioned for the regulated-therapist role within this model.

Sources

1. CRPO. Practice Standards (effective January 1, 2024). https://crpo.ca/practice-standards/
2. CRPO. Standard 6.2 Advertising. https://crpo.ca/practice-standards/business-practices/advertising/
3. CRPO. Psychedelic-Assisted Psychotherapy Resource Article. https://crpo.ca/resource-articles/psychedelic-assisted-psychotherapy/
4. CRPO. Quality Assurance Program Requirements. https://crpo.ca/registrant-information/registrant-requirements/quality-assurance-program/
5. OPQ / Légis Québec. Regulation respecting the psychotherapist's permit (C-26 r.222.1) (current January 1, 2026). https://www.legisquebec.gouv.qc.ca/en/document/cr/C-26,%20r.%20222.1%20/
6. Health Canada (2022). Notice to stakeholders: SAP psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
7. Health Canada (2022). Risk-management measures for clinical trials. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/expectations-risk-management-measures-clinical-trials-psychedelic-assisted-psychotherapy.html
8. CPSA (2026). Ketamine Prescribing, Administration and Oversight Expectations (March 2026). https://cpsa.ca/wp-content/uploads/2026/03/CPSA_Ketamine-Guidance_March-2026.pdf
9. CPSA. Psychedelic-Assisted Psychotherapy Facility Accreditation. https://cpsa.ca/facilities-clinics/accreditation/psychedelic-assisted-psychotherapy/
10. CPSM (2026). Ketamine: What Prescribers and Pharmacists Need to Know. https://www.cpsm.mb.ca/news/ketamine-what-prescribers-and-pharmacists-need-to-know
11. CPSBC (2025). Interim Guidance v1.3 Ketamine non-IV routes. https://www.cpsbc.ca/files/pdf/IG-Ketamine-Administration-via-Intramuscular-Oral-Sublingual-Intranasal-Routes.pdf
12. CAP Alberta (2025). Practice Guideline: Psychedelic-Assisted Psychotherapy (June 2025). https://www.cap.ab.ca/Portals/0/adam/Content/fQCpza4q7EGXC_psrgnCvA/Link/Psychedelic-Assisted%20Psychotherapy%20-%20June%202025.pdf
13. BCACC (2024). Health Canada Guidelines on Psychedelic-Assisted Therapy. https://bcacc.ca/wp-content/uploads/2025/11/Health-Canada-Guidelines-on-Psychedelic-Assisted-Therapy-2024-October.pdf
14. PsyCan (2025). Sharp Decline in Health Canada SAP Approvals (September 2025). https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
15. Flückiger, C. et al. (2018). The alliance in adult psychotherapy: meta-analytic synthesis. Psychotherapy, 55(4), 316–340. https://pubmed.ncbi.nlm.nih.gov/29792475/
16. Murphy, R. et al. (2022). Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Frontiers in Pharmacology, 12, 788155. https://pmc.ncbi.nlm.nih.gov/articles/PMC9009076/
17. Levin, A.W. et al. (2024). The therapeutic alliance and clinical outcomes in a psilocybin-assisted therapy trial. PLOS ONE, 19(3), e0300501. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300501
18. Phelps, J. (2017). Developing Guidelines and Competencies for the Training of Psychedelic Therapists. Journal of Humanistic Psychology, 57(5), 450–487. https://journals.sagepub.com/doi/10.1177/0022167817711304
19. Tai, S.J. et al. (2021). Therapist Training Program for Psilocybin Therapy. Frontiers in Psychiatry, 12, 586682. https://pmc.ncbi.nlm.nih.gov/articles/PMC7908919/
20. Cavarra, M. et al. (2022). Psychedelic-assisted psychotherapy: systematic review of associated psychological interventions. Frontiers in Psychology, 13, 887255. https://pmc.ncbi.nlm.nih.gov/articles/PMC9226617/
21. Drozdz, S.J. et al. (2022). Ketamine Assisted Psychotherapy: Systematic Narrative Review. Journal of Pain Research, 15, 1691–1706. https://pmc.ncbi.nlm.nih.gov/articles/PMC9207256/
22. Wilkinson, S.T. et al. (2017). Cognitive Behavior Therapy May Sustain Antidepressant Effects of IV Ketamine. Psychotherapy and Psychosomatics, 86(3), 162–167. https://pmc.ncbi.nlm.nih.gov/articles/PMC5516265/
23. Yermus, R. et al. (2024). Ketamine-Assisted Psychotherapy at 3 and 6 Months. Psychedelic Medicine, 2(2), 87–95. https://pmc.ncbi.nlm.nih.gov/articles/PMC11613527/
24. Mitchell, J.M. et al. (2021). MDMA-assisted therapy for severe PTSD: Phase 3 MAPP1. Nature Medicine, 27, 1025–1033. https://pmc.ncbi.nlm.nih.gov/articles/PMC8205851/
25. Mitchell, J.M. et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: Phase 3 MAPP2. Nature Medicine, 29, 2473–2480. https://www.nature.com/articles/s41591-023-02565-4
26. Wang, J.B. et al. (2021). Multisite MDMA-AT scaling and fidelity. Journal of Humanistic Psychology. https://journals.sagepub.com/doi/full/10.1177/00221678211023663
27. Goodwin, G.M. et al. (2022). Single-Dose Psilocybin for Treatment-Resistant Depression. NEJM, 387, 1637–1648. https://pubmed.ncbi.nlm.nih.gov/36322843/
28. Raison, C.L. et al. (2023). Single-Dose Psilocybin for MDD. JAMA, 330(9), 843–853. https://pubmed.ncbi.nlm.nih.gov/37651119/
29. Gorman, I. et al. (2021). Psychedelic Harm Reduction and Integration: Transtheoretical Model. Frontiers in Psychology, 12, 645246. https://pmc.ncbi.nlm.nih.gov/articles/PMC8008322/
30. Brennan, W. & Belser, A.B. (2022). EMBARK: Transdiagnostic Trans-Drug Model. Frontiers in Psychology, 13, 866018. https://pmc.ncbi.nlm.nih.gov/articles/PMC9201428/
31. Hartogsohn, I. (2018). Set and setting / meaning-enhancing properties. Frontiers in Neuroscience. https://pmc.ncbi.nlm.nih.gov/articles/PMC5845636/
32. Modlin, N.L. et al. (2024). Trauma-Informed Care in Psychedelic Therapy Research. Neuropsychiatric Disease and Treatment, 20, 109–135. https://pmc.ncbi.nlm.nih.gov/articles/PMC10807282/
33. Dames, S. et al. (2024). Firsthand experience as a training element. Psychedelic Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC11658659/

Related articles in this cluster

• Psychedelic Therapy Training in Canada
• Ketamine-Assisted Psychotherapy Training in Canada
• Psychedelic Therapy Training for Physicians
• Psychedelic Therapy Training for Counsellors
• Psychedelic Therapy Training for Psychologists
• Psychedelic Therapy Training Cost in Canada
• Which Psychedelic Therapy Training Pathway Is Right for Me?
• How to Become a Psychedelic Therapist in Canada
• Clinical Pathway
• Supervised Learning Lab
• Applied Clinical Practice
• Find care near you
• Practitioner FAQs

Last updated: 2026-05-05. Article is reviewed every 6 months.